




The relative strengths and weaknesses of Viracta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 108% points. The greatest weakness of Viracta Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 320%, being 86% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	45,665
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,383
Liabilities, Non-Current	0
Other Assets	130
Other Compr. Net Income	34
Other Expenses	0
Other Liabilities	0
Other Net Income	5,725
Other Revenues	5,000
Property and Equipment	74
Research and Development	22,563
Selling, General and Administrative Expense	8,303

Output Variable	Value in 1000 USD
Assets	45,869
Liabilities	8,383
Expenses	30,866
Revenues	5,000
Stockholders Equity	37,486
Net Income	-20,141
Comprehensive Net Income	-20,124
BaseVar	47,938
ECR before LimitedLiability	227%
Economic Capital Ratio	320%